

**Freedom of Information Act 2000**

**The Royal Cornwall Hospitals NHS Trust Response to Information request**

**Date Request Received: 3<sup>rd</sup> June 2025**

**FOI Ref No 29069**

**Requested Information:**

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel
- Atezolizumab
- Capivasertib
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Elacestrant
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)
- Pembrolizumab Monotherapy
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab
- Carboplatin + Paclitaxel + Pembrolizumab
- Pertuzumab (Pertega) + Trastuzumab (Herceptin)
- Phesgo (Pertuzumab + Trastuzumab in a single injection)
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
- Trastuzumab emtansine (Kadcyla)
- Any other active systemic anti-cancer therapy
- Aromatase Inhibitor as a single agent

Q2. How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies:

- Phesgo (Pertuzumab + Trastuzumab in a single injection)
- Pertuzumab (Perteja) + Trastuzumab (Herceptin)
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab emtansine (Kadcyla)
- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Carboplatin + Paclitaxel + Pembrolizumab

Q3. Does your trust participate in any Clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

### Response:

#### Data for Feb 2025 – Apr 2025

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **34**
- Abemaciclib + Fulvestrant **2**
- Alpelisib + Fulvestrant **0**
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide **2**
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel **6**
- Atezolizumab **3**
- Capivasertib **1**
- Capecitabine as a single agent **17**
- Carboplatin + Paclitaxel **21 (20 of these sequential with EC)**
- Elacestrant **2**
- Eribulin as a single agent or in combination **5**
- Everolimus + Exemestane **3**
- Fulvestrant as a single agent **21**
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **54**
- Palbociclib + Fulvestrant **12**
- Parp Inhibitors (Olaparib/Talazoparib) **2**
- Pembrolizumab Monotherapy **4**

- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab
  - **21 patients on pembrolizumab with chemotherapy – it is not possible to break down whether they are on the EC or the carboplatin/paclitaxel phase**
- Carboplatin + Paclitaxel + Pembrolizumab
  - **21 patients on pembrolizumab with chemotherapy – it is not possible to break down whether they are on the EC or the carboplatin/paclitaxel phase**
- Pertuzumab (Perteja) + Trastuzumab (Herceptin) **1**
- Phesgo (Pertuzumab + Trastuzumab in a single injection) **36**
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **50**
- Ribociclib + Fulvestrant **12**
- Sacituzumab Govitecan **5**
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent **33**
- Trastuzumab deruxtecan (Enhertu) **8**
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel **23**
- Trastuzumab emtansine (Kadcyla) **5**
- Any other active systemic anti-cancer therapy
  - Carboplatin single agent – **6**
  - Denosumab - **124**
  - EC-Docetaxel – **11**
  - EC-THP – **7**
  - Epirubicin single agent – **3**
  - FEC -**1**
  - Vinorelbine – **4**
  - Zoledronic acid – **136**
  - TC – **2**
  - TCH – **1**
  - TCHP - **10**
- Aromatase Inhibitor as a single agent **156**

Q2. How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies:

- Phesgo (Pertuzumab + Trastuzumab in a single injection) **1**
- Pertuzumab (Perteja) + Trastuzumab (Herceptin) **26**
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel **8**
- Trastuzumab deruxtecan (Enhertu) **8**
- Trastuzumab emtansine (Kadcyla) **2**
- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **4**
- Abemaciclib + Fulvestrant **2**
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) **49**

- Ribociclib + Fulvestrant **12**
- Capecitabine as a single agent **16**
- Carboplatin + Paclitaxel **1**
- Carboplatin + Paclitaxel + Pembrolizumab **0**

Q3. Does your trust participate in any Clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

- **Please see appendix one**

**Attachment(s):**

Appendix one - FOI 29069 Breast Cancer Clinical Trials Response

**Date Response sent: 23<sup>rd</sup> June 2025**